• Explore /
  • Poster
  • / Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.

Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.

Abstract Poster

Authors

null

Matthew Reilley

University of Virginia, Charlottesville, VA

Matthew Reilley , Apostolia Maria Tsimberidou , Sarina Anne Piha-Paul , Timothy A Yap , Siqing Fu , Aung Naing , Jordi Rodon , Ly Minh Nguyen , Casey Ager , Martin Meng , Priyamvada Jayaprakash , Manuel Schmidt , Matthias Baumann , Funda Meric-Bernstam , Michael A. Curran , David S. Hong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT02668770

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS2669)

DOI

10.1200/JCO.2019.37.15_suppl.TPS2669

Abstract #

TPS2669

Poster Bd #

300b

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.

Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.

First Author: Mirella Nardo

First Author: Toni K. Choueiri

First Author: Kamaneh Montazeri

First Author: Alberto Fusi